%0 Journal Article %A Hannes Treiber %A Alexander König %A Albrecht Neesse %A Annika Richter %A Carsten Oliver Sahlmann %A Arne Strauss %T Liver Enzyme Elevation After 177Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer %D 2021 %R 10.2967/jnumed.120.258533 %J Journal of Nuclear Medicine %P 1016-1019 %V 62 %N 7 %X 177Lu-PSMA radioligand therapy is a promising new option for patients with metastasized castration-resistant prostate cancer, and the spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a patient with M1c disease (metastasis to the mediastinum, lungs, bones, and liver) who presented with elevated liver enzyme levels after receiving 177Lu-PSMA radioligand therapy for castration-resistant prostate cancer. Pretreatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently. %U https://jnm.snmjournals.org/content/jnumed/62/7/1016.full.pdf